Nijmegen, 13 February 2017
ORCA Therapeutics B.V. has successfully completed the GLP compliant toxicology and safety studies with their lead product ORCA-010. ORCA-010 is a powerful oncolytic adenovirus that selectively kills cancer cells and induces an antitumor immune response, without being harmful to normal cells. The studies demonstrated that intraprostatic injection and repeat intravenous treatment with ORCA-010 in an animal model permissive for human adenovirus replication was well tolerated and without dose limiting adverse effects.
Upon intraprostatic injection, ORCA-010 remains primarily in the prostate. Injected ORCA-010 also reaches draining lymph nodes and the liver, which are common prostate cancer metastatic sites, and the bladder, a common site for prostate cancer invasion.
“We are excited to observe the attractive safety profile of ORCA-010, knowing that ORCA-010 is much more powerful in killing cancer cells than earlier generation oncolytic adenoviruses”
The completion of preclinical studies is a key milestone in preparation for ORCA’s clinical trial in patients with locally recurrent prostate cancer. “We are excited to observe the attractive safety profile of ORCA-010, knowing that ORCA-010 is much more powerful in killing cancer cells than earlier generation oncolytic adenoviruses” says Victor van Beusechem, CSO of ORCA Therapeutics. “These characteristics motivate us to further pursue clinical development of ORCA-010.”
About ORCA Therapeutics
ORCA Therapeutics is a Dutch biopharmaceutical company developing innovative oncolytic immunotherapies for the treatment of cancer. The company has a platform of technologies to engineer highly potent oncolytic adenoviruses. ORCA’s lead product ORCA-010 is a powerful oncolytic adenovirus that exhibits strong oncolytic potency in different cancer types in vitro and in vivo.
Download a copy of this announcement.